From mitochondrial signal to discovery decision: a reserve-demand framework for translational risk assessment

Mitochondrial safety assessment is used in drug discovery, supported by bioenergetic profiling, mechanistic assays, human-relevant cellular systems, and multidimensional data. These advances have improved detection of mitochondrial perturbation but have not solved the harder problem: how such signals should be interpreted and translated into discovery decisions.

This perspective proposes a qualitative decision-centered framework for interpreting mitochondrial findings. This framework is anchored in reserve-demand biology, which explains why mitochondrial perturbations become consequential when drug-induced reductions in bioenergetic capacity intersect with tissue-specific demand, exposure, duration, and stress context. Furthermore, the authors describe a qualitative Translational Risk Profile organized around mechanistic severity, exposure relevance, temporal progression, and translational concordance. This profile is paired with a Decision Taxonomy: Stop, Optimize, Monitor, or Acceptable Risk. Examples illustrate how mitochondrial evidence patterns can support different discovery actions.

The major limitation in mitochondrial safety assessment is no longer signal detection, but decision-oriented interpretation. Future progress will depend on integrating mechanism, exposure, duration, biomarkers, human-relevant models and quantitative or computational evidence into explicit decision frameworks. Mitochondrial findings should not be treated as binary hazards. They should be interpreted as context-dependent evidence that can guide chemistry, candidate selection, monitoring strategy, and translational risk management.